Mitochondrial modulators for bipolar disorder: A pathophysiologically informed paradigm for new drug development
about
Beyond Monoamines-Novel Targets for Treatment-Resistant Depression: A Comprehensive ReviewPharmacological approaches to the challenge of treatment-resistant depression1H-NMR, 1H-NMR T2-edited, and 2D-NMR in bipolar disorder metabolic profilingTreatment of mitochondrial disorders.Investigation of manic and euthymic episodes identifies state- and trait-specific gene expression and STAB1 as a new candidate gene for bipolar disorderMultiple levels of impaired neural plasticity and cellular resilience in bipolar disorder: developing treatments using an integrated translational approachSex-specific urinary biomarkers for diagnosing bipolar disorder.DSM-5: a collection of psychiatrist views on the changes, controversies, and future directions.Calcium-dependent intracellular signal pathways in primary cultured adipocytes and ANK3 gene variation in patients with bipolar disorder and healthy controls.Perturbational Profiling of Metabolites in Patient Fibroblasts Implicates α-Aminoadipate as a Potential Biomarker for Bipolar Disorder.Stress, Inflammation, and Cellular Vulnerability during Early Stages of Affective Disorders: Biomarker Strategies and Opportunities for Prevention and Intervention.Mitochondrial dysfunction in psychiatric and neurological diseases: cause(s), consequence(s), and implications of antioxidant therapy.Coenzyme Q10 depletion in medical and neuropsychiatric disorders: potential repercussions and therapeutic implications.Role of immune-inflammatory and oxidative and nitrosative stress pathways in the etiology of depression: therapeutic implications.A mitochondrial bioenergetic basis of depression.Biological hypotheses and biomarkers of bipolar disorder.Proteomic analysis of the postsynaptic density implicates synaptic function and energy pathways in bipolar disorder.Tissue Type-Specific Bioenergetic Abnormalities in Adults with Major Depression.Mitochondrial modulators improve lipid composition and attenuate memory deficits in experimental model of Huntington's disease.A randomized, double-blind, placebo-controlled, proof-of-concept trial of creatine monohydrate as adjunctive treatment for bipolar depression.Endogenous cardiac steroids in animal models of mania.Design and rationale of a 16-week adjunctive randomized placebo-controlled trial of mitochondrial agents for the treatment of bipolar depression.Mitochondrial Agents for Bipolar Disorder.Na⁺, K⁺-ATPase Signaling and Bipolar Disorder
P2860
Q26782993-9B77ED84-DB98-4024-A3E9-7B6421A3EEAFQ26798241-947BA1FF-9643-4E61-AA44-D07801D2EB43Q33760065-51138874-CCDD-4E82-9BDF-510F1D4FD5A2Q33794684-B3E8BF1C-751B-4F06-BA12-AB05DB719C4FQ34113404-95C41046-0249-4FAC-A469-450D3AFFB672Q34268501-AE45D237-B3DF-4117-B681-8AB493F17540Q34757521-A092CBA0-02D9-4660-9F75-74CD88B623BCQ35042639-FB990315-311A-4BCB-BF28-19E3DAED8B7EQ36594531-6A70ED2F-CF55-492A-88FA-6B015C1EEE7CQ37200180-796307B4-808A-429D-B5BD-E91698B6C3A5Q37705451-7705DAE4-4E3C-4891-AF96-D9719C49B344Q38086474-A0C994B4-1189-4122-ADC1-43E144BF35C2Q38114007-79042E52-E6E1-4551-87B9-925A1E0D2C81Q38154840-EFC2747C-8851-4DF4-B0AE-9826A8539F69Q38254909-444E9B02-52FF-431A-9004-46B064C062FDQ38995726-01F456B5-8BB3-42EC-A5A5-7BCA5161D048Q39145749-4B322706-4262-4816-AA37-324FE5EA8C62Q39431425-EC75B66B-E70D-4A04-8EA9-C9C2FDE817DAQ45290056-81C0E5B7-938D-4FB7-9938-F8DCE1DBEF5BQ47695444-DA3F83A1-6FD9-4BF4-9C04-5D9685FF5798Q48049414-54A5DC62-8948-4956-AE1F-31AD19827563Q48195966-CFE54F74-00A7-40F5-BC64-9C180E6E3750Q52621890-EF776A8D-CACE-4D7D-8CFD-C785A70ED5A9Q58796804-DF40122F-182E-4123-A74D-36AC7AA0C5D9
P2860
Mitochondrial modulators for bipolar disorder: A pathophysiologically informed paradigm for new drug development
description
2012 nî lūn-bûn
@nan
2012 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2012 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
name
Mitochondrial modulators for b ...... adigm for new drug development
@ast
Mitochondrial modulators for b ...... adigm for new drug development
@en
Mitochondrial modulators for b ...... adigm for new drug development
@nl
type
label
Mitochondrial modulators for b ...... adigm for new drug development
@ast
Mitochondrial modulators for b ...... adigm for new drug development
@en
Mitochondrial modulators for b ...... adigm for new drug development
@nl
altLabel
Mitochondrial modulators for b ...... adigm for new drug development
@en
prefLabel
Mitochondrial modulators for b ...... adigm for new drug development
@ast
Mitochondrial modulators for b ...... adigm for new drug development
@en
Mitochondrial modulators for b ...... adigm for new drug development
@nl
P2093
P2860
P921
P356
P1476
Mitochondrial modulators for b ...... adigm for new drug development
@en
P2093
A. A. Nierenberg
B. P. Brennan
D. V. Iosifescu
R. C. Shelton
P2860
P356
10.1177/0004867412449303
P407
P577
2012-06-18T00:00:00Z